---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-196384"
form_type: "8-K"
ticker: "CLYM"
cik: "0001768446"
company_name: "Climb Bio, Inc."
filed_at: "2022-07-18T23:59:59+00:00"
generated_at: "2026-06-24T13:33:07.262610+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Eliem delays ETX-155 Phase 2a MDD trial to Q1 2023 after lower exposure in PSE trial; CMC issue identified

## Summary
- Lower-than-expected ETX-155 exposure in Phase 1b photosensitive epilepsy trial attributed to CMC batch inconsistencies.
- Phase 1 PK trial in healthy subjects expected Q4 2022 to determine dose for Phase 2a MDD trial.
- Phase 2a MDD trial now expected to start Q1 2023 with topline data in mid-2024.
- Phase 2a PMD trial postponed to preserve investment flexibility; PSE trial paused pending PK data.
- Cash ($149.9M as of March 2022) expected to fund operations and pipeline catalysts through mid-2024.

## SEC filing metadata
- accession: 0001193125-22-196384
- form_type: 8-K
- ticker: CLYM
- cik: 0001768446
- company_name: Climb Bio, Inc.
- filed_at: 2022-07-18T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1768446/000119312522196384/0001193125-22-196384-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1768446/000119312522196384/d385261d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-196384
- JSON: https://secwatch.observer/filing/0001193125-22-196384.json
- Plain text: https://secwatch.observer/filing/0001193125-22-196384.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.